Dalteparin may be an effective alternative to UFH for treatment of APS in pregnancy. A multicentre randomized trial is needed to determine benefit-to-risk ...

7 февр. 2024 г. · Unfractionated heparin must be injected twice per day and has a risk of causing excessive bleeding, a low platelet count, and osteoporosis.

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the persistent positivity of antiphospholipid antibodies (aPLA) together ...

High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening for and ...

Dalteparin may be an effective alternative to UFH for treatment of APS in pregnancy. A multicentre randomized trial is needed to determine benefit-to-risk ...

Dalteparin may be an effective alternative to UFH for treatment of APS in pregnancy. A multicentre randomized trial is needed to determine benefit-to-risk ...

Dalteparin Terminated Phase 0 Trials for Antiphospholipid Syndrome in Pregnancy / Pregnancy Loss Treatment · Acetylsalicylic acid (DB00945) · Dalteparin (DB06779) ...

3 сент. 2009 г. · This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS). Venous thrombosis · Arterial thrombosis · Obstetric APS

El síndrome de anticuerpos antifosfolipídicos catastrófico se trata con una combinación de anticoagulación, corticoides y recambios plasmáticos.

1 мар. 2006 г. · Antiphospholipid antibody syndrome (APS) refers to the association between antiphospholipid antibodies and thrombosis risk or pregnancy morbidity.